Nanofilm FY2025 revenue at S$244.6 million, profit at S$11.9 million on AMBU demand and IEBU recovery

SGX Filings
02/25

Nanofilm Technologies International Limited reported profit after tax of S$11.9 million for the 12 months ended Dec 31 2025, up 58% year-on-year, lifted by sustained growth in its Advanced Materials Business Unit (AMBU) and a rebound in Industrial Equipment sales.

Group revenue rose 20% to S$244.6 million, while adjusted EBITDA increased 21% to S$62.8 million, driving a 30-basis-point improvement in the adjusted EBITDA margin to 25.7%. The board proposed a final dividend of 0.87 Singapore cents a share, bringing the FY2025 payout to 1.20 Singapore cents.

AMBU remained the principal revenue engine, expanding 20% YoY to S$206.9 million on new and existing consumer electronics programmes and contributions from industrial customers in Europe. IEBU revenue surged 50% to S$17.0 million, supported by higher demand for next-generation mould coaters and solar equipment. NFBU recorded modest growth of 0.7% to S$18.2 million, while hydrogen-focused subsidiary Sydrogen posted a 9.8% revenue decline to S$2.5 million as some customer orders were deferred.

Group gross profit margin slipped to 36.2% from 37.1% in FY2024, weighed down by higher interim manpower costs during product ramp-ups; however, second-half GPM rebounded to 38.9% as operations stabilised. Second-half PAT eased 6% YoY to S$10.5 million after a S$3.6 million loss from the closure and write-off of workshops.

Looking ahead, Nanofilm plans to deepen its “China Plus One” manufacturing strategy by expanding capacity in Vietnam and India and broadening its European footprint. Management forecasts balanced growth in the consumer-focused coatings segment, double-digit expansion in industrial and automotive applications, and continued momentum in equipment sales. NFBU is targeting double-digit growth in 2026 on new 3C health-sensing and flash-lens projects, while Sydrogen seeks to scale fuel-cell-related coatings following successful certification tests.

The group said it has largely completed a major capital-expenditure cycle and will prioritise higher utilisation of existing assets, tighter cost controls and improved cash generation, with the overarching objectives of achieving faster revenue growth, stronger profitability and enhanced shareholder returns.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10